drugset / Trial / NCT05966441

Role of Curcumin in Paclitaxel Induced PN

NCT05966441

Phase 2 Unknown 80 enrolled Ain Shams University
RandomizedParallel-groupOpen-labelPrevention

Summary

Paclitaxel induced peripheral neuropathy is the most common and serious side effect associated with Paclitaxel treatment in breast cancer patients receiving Paclitaxel. The efficacy of antioxidant molecules as neuroprotective strategies to preventing the development of peripheral neuropathy has been investigated in preclinical and clinical studies. Vitamin E and Glutathione have been explored as adjuvant therapies to preventing taxane-induced peripheral neuropathy. Other tested neuroprotective treatments with limited success include amifostine, glutamine and acetyl l-carnitine. Curcumin's antioxidant capacity is similar to other potent antioxidants, such as trolox (a vitamin E analog). Curcumin inhibits lipid peroxidation in different tissues, regulates intracellular levels of antioxidant enzymes (e.g., catalase, glutathione peroxidase and superoxide dismutase) and is an effective intracellular reactive oxygen species (ROS) scavenger. The investigators are going to investigate the neuroprotective effect of Curcumin against Paclitaxel induced peripheral neuropathy.

Timeline

Start
2023-08-30
Primary completion
2023-12-15
Completion
2024-03-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Curcumin Small molecule 2 g Oral
Background Paclitaxel Small molecule 80 mg/m2 Intravenous
Background Paclitaxel Small molecule 175 mg/m2 Intravenous